Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016107 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00016107: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00016107 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 72 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00016107, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of combination chemotherapy plus monoclonal antibody therapy in treating patients who have metastatic prostate cancer that has not responded to previous hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab may stop the growth of cancer cells by stopping blood flow to the tumor. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG docetaxel
- BIOLOGICAL bevacizumab
- DRUG estramustine phosphate sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2001-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016107
The ClinicalTrials.gov registry entry for NCT00016107 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00016107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00016107 about?
NCT00016107 is a clinical study titled "Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer". Phase II trial to study the effectiveness of combination chemotherapy plus monoclonal antibody therapy in treating patients who have metastatic prostate cancer that has not responded to previous hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they ...
What is the current status of trial NCT00016107?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2001-06.
What interventions are being tested in trial NCT00016107?
The interventions under investigation include: laboratory biomarker analysis (OTHER), docetaxel (DRUG), bevacizumab (BIOLOGICAL), estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00016107?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.